



ASX / Media Release  
15th December 2015

## **OncoSil Medical appoints Charles Rowland President of US operations**

### **Former Sirtex US President to drive US FDA licensing & commercialisation process**

**SYDNEY, 15th December, 2015: OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company)** is pleased to announce the appointment of Mr. Charles Rowland as President, OncoSil Medical USA.

Mr. Rowland was previously President of Sirtex Medical US from 2002 to 2006, and is a highly experienced healthcare executive with a successful record of commercialising medical devices and growing medical device companies in the diagnostics, cardiac patient management and liver cancer markets.

In his role with OncoSil Medical Mr. Rowland will be responsible for developing and executing the Company's US Business plan and will be the Company's official representative with the US FDA as it works towards US licensure for its lead product candidate, the OncoSil™ localised radiation treatment for cancer.

Mr. Rowland will work with the Company's medical and regulatory team and with Key Opinion Leaders as the Company moves forward with the introduction of OncoSil™ into the US market.

During his tenure with Sirtex Medical Mr. Rowland was responsible for establishing the team that launched and commercialised SIR-Spheres in the US market. Under his management, Sirtex's US business grew to almost \$20 million, accounting for over 80% of Sirtex Medical's global revenues at the time. Mr. Rowland served on the Sirtex board of directors from 2003 to 2006.

Mr. Rowland has an MBA from the London Business School and an Economics degree from Bristol University.

Commenting on the appointment OncoSil Medical CEO, Daniel Kenny said:

*"We are delighted to announce the appointment of Mr Charles Rowland as President of our USA operations. His is a key appointment as we move into a highly significant phase in the licensing & commercialisation of OncoSil™, in the US market. Charles's specific, relevant experience and success in the medical device space makes him the ideal candidate to drive our development and commercialisation goals in the US market, and I and the rest of the OncoSil Medical management team look forward to working closely with him to help ensure a successful licensing pathway and outcome for OncoSil™ in the US."*

ENDS

Contact:

ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL  
Suite 807, Level 8, 1 Alfred Street Sydney NSW 2000 AUSTRALIA  
TELEPHONE +61 2 9223 3344 FACSIMILE +61 2 9221 8535  
WEB [www.oncosil.com.au](http://www.oncosil.com.au)

**Mr Daniel Kenny**  
**Chief Executive Officer and Managing Director**  
E: [daniel.kenny@oncosil.com.au](mailto:daniel.kenny@oncosil.com.au)  
T: +61 2 9223 3344

**James Moses**  
**Mandate Corporate**  
E: [james@mandatecorporate.com.au](mailto:james@mandatecorporate.com.au)  
M: +61 420 991 574  
T: +61 2 8211 0612

### **About OncoSil Medical Ltd**

OncoSil Medical Ltd (OncoSil Medical) is a clinical-stage Australian Lifesciences company with the aim is to provide new technologies for safer medical radiation treatments. OncoSil Medical's lead product is OncoSil™ with the first target indication being pancreatic cancer. OncoSil™ is a silicon and P32 (phosphorus) pure beta emitter with the potential to be used medically as a brachytherapy treatment. The OncoSil™ device delivers more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has previously conducted four clinical trials with encouraging results on tolerability, safety and efficacy. There is also potential use for OncoSil™ in other solid tumours outside of pancreatic cancer. FDA and CE Mark approval for pancreatic cancer is the core focus of OncoSil Medical.

### **Pancreatic Cancer**

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

### **Hepatocellular carcinoma liver cancer**

Hepatocellular carcinoma (HCC) is the 6<sup>th</sup> most common cancer in the world with 782,000 new cases diagnosed in 2012. It's very poor prognosis makes HCC the third leading cause of cancer related mortality responsible for approximately 600,000 deaths annually. Hepatocellular carcinoma can be cured by surgery or transplantation. The vast majority of patients with HCC have disease which is too advanced for surgical intervention and as a consequence survival ranges from a few months to two or more years depending on the liver function at diagnosis and the extent of tumour invasion. The value of the hepatocellular cancer (HCC) market is expected to triple in size to \$1.4b by 2019.

### **References**

- Global Industry Analysts 2010
- BIOSDP-201. A single dose, single centre open label Phase I/II Safety Study in Hepatocarcinoma
- Venook et al. The incidence of Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. The Oncologist; 15 Supplement 5-13
- <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/pancreatic-cancer-statistics>
- <http://www.datamonitorhealthcare.com/hepatocellular-cancer-market-to-treble-in-size-by-2019>
- <http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/liver-cancer-statistics>